Aptah Bio is a biotech startup focused on novel RNA therapies initially targeting cancer and neurodegenerative diseases. We aim to develop a new generation of RNA therapies for the treatment of sporadic genetic disorders based on a proprietary molecule class capable of modulating the spliceosome and other elements of the transcription processes in an unprecedented way, by targeting small nuclear ribonucleoproteins. It was founded in 2018 by MSc. Caio Bruno Leal (CSO) and has been led since 2020 by the CEO Rafael Bottos.